“GLP-1s inevitably leave you with loose, saggy skin.”
What the evidence shows
Loose or excess skin is a real, well-recognized consequence of large weight loss by any route — bariatric surgery, illness, or crash dieting all produce it. Skin has finite elasticity: when the fat beneath it shrinks faster than the skin can retract, some laxity can remain, especially after big losses. Dermatology reviews of GLP-1 users describe skin changes as a downstream effect of systemic fat loss, not a direct action of the medicine on skin. Because typical GLP-1 weight loss (roughly 15–20% of body weight) is usually less extreme than the losses after bariatric surgery, severe redundant skin is less common than the "inevitable" framing suggests.
What we still don’t know
How much loose skin any individual ends up with — and how much retracts over time — isn't precisely predictable. It depends on age, genetics, how much and how fast weight comes off, sun damage, and baseline skin quality, and the volume estimates come from small cohorts rather than large trials. Whether slower, more gradual loss meaningfully reduces it is plausible but not firmly quantified.
Why the claim misleads
"Inevitably" turns a variable, dose- and speed-dependent outcome into a guaranteed one. Many people with modest losses see little or no lasting laxity; those with very large or very rapid losses see more. It's a possible cosmetic tradeoff of substantial weight loss — one where pace of loss, muscle preservation, and options a clinician or dermatologist can discuss all matter — not a certainty the drug imposes on everyone.
Source: A Closer Look at the Dermatological Profile of GLP-1 Agonists (Diseases, 2025)
Graded by The Peptide Era · evidence, not hype